FinTechFunding

Starpharma: Receives $1M MRFF funding for COVID-19 nasal spray

  • Starpharma (SPL) has been awarded $1M in matched funding by the Australian Government’s Medical Research Future Fund (MRFF)
  • This funding will also enable the pharmaceutical company to speed-up development and commercialisation of its COVID-19 antiviral nasal spray
  • Starpharma’s nasal spray is based on its proprietary dendrimer, SPL7013, which has demonstrated significant activity against SARS-CoV-2, the virus that causes COVID-19
  • SPL7013 works by blocking the interaction between viral surface proteins and human cell receptor proteins
  • SPL7013 has also shown potential treatment for other diseases such as HIV, herpes, hepatitis B, and the Zika virus
  • Starpharma is up 4.29 per cent on the market and shares are trading for $1.70 each
Previous article
Dorian: Raises $3.25M in Seed Funding
Next article
AML3D: Signs contract with Austal
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

eToro Strengthens Crypto Portfolio with Zengo Acquisition

Deal expands eToro's offerings in the cryptocurrency sector.Highlights: eToro is acquiring crypto wallet Zengo to expand its services.The...
FinTech

Revolut Launches Platform to Streamline Overseas Talent Hiring

Revolut's new service aims to simplify global recruitment for businesses.Highlights: Revolut launches a platform for hiring overseas talent.The...
FinTech

Revolut Strengthens Business Recruitment Platform in New Markets

The fintech giant expands its offerings targeting recruitment needs globally.Highlights: Revolut enhances its platform for business recruitment.The expansion...
FinTech

UniCredit Selects Slate to Strengthen Retail Investment Services

The partnership aims to enhance digital investment options for customers.Highlights: UniCredit partners with Slate for enhanced retail investment...